on Bausch Health Companies Inc. (NASDAQ:BHC)
Bausch Health Decides Against Sale of Bausch + Lomb
Bausch Health Companies Inc. announced that it will not proceed with the sale of its subsidiary, Bausch + Lomb Corporation. The decision follows a review of a private equity firm's proposal, which was deemed not reflective of Bausch + Lomb's long-term potential. Consequently, Bausch Health will retain its 88% interest in the subsidiary.
In 2024, Bausch Health sought advice on liability management and engaged with Bausch + Lomb concerning the company's separation. Despite interest in a complete separation, the boards opted not to pursue the sale. Bausch Health plans to explore other liability management strategies, including new debt financing.
The company remains focused on enhancing business performance, reflected by adjustments in its 2024 revenue and earnings guidance. Bausch Health will release its full 2024 financial results and 2025 guidance on February 19, 2025.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Bausch Health Companies Inc. news